Efficacy and safety of Camrelizumab combined with Abraxane + lobaplatin regimen for advanced gastric cancer

Purpose: To examine the safety and effectiveness of the combination of Camrelizumab and Abraxane + lobaplatin in advanced gastric cancer therapy.

Methods: The data of 60 patients with advanced gastric cancer in Shaanxi Provincial People’s Hospital from May 2017 to March 2019 were analyzed retrospectively.

The patients were divided into a study group (n=30) and a control group (n=30) according to different treatment methods.

The study group received Camrelizumab combined with the Abraxane + lobaplatin regimen, and the control group received the Abraxane + lobaplatin regimen only.

The levels of soluble interleukin-2 receptor (sIL-2R), secretory glycoprotein (Dickkopf-1, DKK-1) and tumor specific growth factors (TSGFs), the relative molecular expression of serum miRNA-1290, miRNA-647 and miRNA-182, and the Karnofsky performance status (KPS) were compared between the two groups.

The adverse reactions of the two groups were observed, and the 3-year survival rates were compared.

Results: The disease control rate and overall remission rate of the study group (53.33%, 90.00%) were higher than those of the control group (26.67%, 50.00%), with statistically significant differences (P<0.05).

The levels of sLL-2R, DKK-1 and TSGF were reduced in both groups (P<0.05) after being treated, whereas these were comparatively lower levels in the study group (P<0.05).

After treatment, serum concentration of miRNA-1290, miRNA-647 and miRNA-182 were lower in the study group than in the control group (P<0.05).

Upon comparison with those in the control group, the KPS scores were higher at 1, 3 and 6 months after treatment in the study group (P<0.05).

The incidence of adverse events was not significantly different between the two groups (P>0.05).

The 1-year, 2-year and 3-year survival rates were higher in the study group (57.38%, 39.34% and 29.51%) than in the control group (32.79%, 18.03% and 8.20%) (P<0.05).

Conclusion: The combination of Camrelizumab and Abraxane + lobaplatin is an effective treatment for advanced gastric cancer and can increase the patient’s survival rate.